TY - JOUR
T1 - Mithramycin for Paget's Disease of Bone
AU - Ryan, Will G.
AU - Haddad, John G.
AU - Birge, Stanley J.
AU - Avioli, Louis V.
PY - 1970/11/19
Y1 - 1970/11/19
N2 - To the Editor: I was quite interested, on reading the article of Haddad et al. on the effects of prolonged thyrocalcitonin administration on Paget's disease of bone (New Eng J Med 283:549, 1970), by their somewhat cavalier dismissal of the use of mithramycin in this disorder because of “unacceptable side effects.” We have now treated more than 40 such patients with mithramycin (JAMA 21:1153, 1970), with no serious toxicity and with much more dramatic effects, including prolonged remissions of disease activity. Although careful monitoring of the patient during administration of the drug is necessary to avoid serious toxicity, we believe.
AB - To the Editor: I was quite interested, on reading the article of Haddad et al. on the effects of prolonged thyrocalcitonin administration on Paget's disease of bone (New Eng J Med 283:549, 1970), by their somewhat cavalier dismissal of the use of mithramycin in this disorder because of “unacceptable side effects.” We have now treated more than 40 such patients with mithramycin (JAMA 21:1153, 1970), with no serious toxicity and with much more dramatic effects, including prolonged remissions of disease activity. Although careful monitoring of the patient during administration of the drug is necessary to avoid serious toxicity, we believe.
UR - http://www.scopus.com/inward/record.url?scp=0014955283&partnerID=8YFLogxK
U2 - 10.1056/NEJM197011192832120
DO - 10.1056/NEJM197011192832120
M3 - Letter
C2 - 5474359
AN - SCOPUS:0014955283
SN - 0028-4793
VL - 283
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 21
ER -